Cargando…

Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents

Radiopharmaceuticals serve as a major part of nuclear medicine contributing to both diagnosis and treatment of several diseases, especially cancers. Currently, most radiopharmaceuticals are based on small molecules with targeting ability. However, some concerns over their stability or non-specific i...

Descripción completa

Detalles Bibliográficos
Autores principales: Winuprasith, Thunnalin, Koirala, Pankaj, McClements, David J, Khomein, Piyachai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406121/
https://www.ncbi.nlm.nih.gov/pubmed/37555189
http://dx.doi.org/10.2147/IJN.S416737
_version_ 1785085681570152448
author Winuprasith, Thunnalin
Koirala, Pankaj
McClements, David J
Khomein, Piyachai
author_facet Winuprasith, Thunnalin
Koirala, Pankaj
McClements, David J
Khomein, Piyachai
author_sort Winuprasith, Thunnalin
collection PubMed
description Radiopharmaceuticals serve as a major part of nuclear medicine contributing to both diagnosis and treatment of several diseases, especially cancers. Currently, most radiopharmaceuticals are based on small molecules with targeting ability. However, some concerns over their stability or non-specific interactions leading to off-target localization are among the major challenges that need to be overcome. Emulsion technology has great potential for the fabrication of carrier systems for radiopharmaceuticals. It can be used to create particles with different compositions, structures, sizes, and surface characteristics from a wide range of generally recognized as safe (GRAS) materials, which allows their functionality to be tuned for specific applications. In particular, it is possible to carry out surface modifications to introduce targeting and stealth properties, as well as to control the particle dimensions to manipulate diffusion and penetration properties. Moreover, emulsion preparation methods are usually simple, economic, robust, and scalable, which makes them suitable for medical applications. In this review, we highlight the potential of emulsion technology in nuclear medicine for developing targeted radionuclide therapies, for use as radiosensitizers, and for application in radiotracer delivery in gamma imaging techniques.
format Online
Article
Text
id pubmed-10406121
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104061212023-08-08 Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents Winuprasith, Thunnalin Koirala, Pankaj McClements, David J Khomein, Piyachai Int J Nanomedicine Review Radiopharmaceuticals serve as a major part of nuclear medicine contributing to both diagnosis and treatment of several diseases, especially cancers. Currently, most radiopharmaceuticals are based on small molecules with targeting ability. However, some concerns over their stability or non-specific interactions leading to off-target localization are among the major challenges that need to be overcome. Emulsion technology has great potential for the fabrication of carrier systems for radiopharmaceuticals. It can be used to create particles with different compositions, structures, sizes, and surface characteristics from a wide range of generally recognized as safe (GRAS) materials, which allows their functionality to be tuned for specific applications. In particular, it is possible to carry out surface modifications to introduce targeting and stealth properties, as well as to control the particle dimensions to manipulate diffusion and penetration properties. Moreover, emulsion preparation methods are usually simple, economic, robust, and scalable, which makes them suitable for medical applications. In this review, we highlight the potential of emulsion technology in nuclear medicine for developing targeted radionuclide therapies, for use as radiosensitizers, and for application in radiotracer delivery in gamma imaging techniques. Dove 2023-08-03 /pmc/articles/PMC10406121/ /pubmed/37555189 http://dx.doi.org/10.2147/IJN.S416737 Text en © 2023 Winuprasith et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Winuprasith, Thunnalin
Koirala, Pankaj
McClements, David J
Khomein, Piyachai
Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title_full Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title_fullStr Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title_full_unstemmed Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title_short Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
title_sort emulsion technology in nuclear medicine: targeted radionuclide therapies, radiosensitizers, and imaging agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406121/
https://www.ncbi.nlm.nih.gov/pubmed/37555189
http://dx.doi.org/10.2147/IJN.S416737
work_keys_str_mv AT winuprasiththunnalin emulsiontechnologyinnuclearmedicinetargetedradionuclidetherapiesradiosensitizersandimagingagents
AT koiralapankaj emulsiontechnologyinnuclearmedicinetargetedradionuclidetherapiesradiosensitizersandimagingagents
AT mcclementsdavidj emulsiontechnologyinnuclearmedicinetargetedradionuclidetherapiesradiosensitizersandimagingagents
AT khomeinpiyachai emulsiontechnologyinnuclearmedicinetargetedradionuclidetherapiesradiosensitizersandimagingagents